Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.

I call it my AI Retirement Playbook. I recommend you check it out now.

Kenneth Pienta Biography and Net Worth

Insider of Cue Biopharma

Kenneth Pienta is a highly-respected leader in the understanding of cancer metastases and the role of the tumor microenvironment in cancer development and immunosuppression. Dr. Pienta is the Donald S. Coffey Professor of Urology, as well as a Professor of Oncology, Pharmacology and Molecular Sciences, and Chemical and Biomolecular Engineering at Johns Hopkins University. Currently, he is the Director of Research at the Brady Urological Institute and also serves as the co-Director of the Johns Hopkins Individualized Health Initiative (Hopkins inHealth) to better define the practice of precision medicine. He has been the principal investigator on numerous local and national clinical trials and has a proven track record in developing multi-disciplinary translational research programs, diagnostics, and therapeutics. Dr. Pienta is the author of more than 350 peer-reviewed articles, and is a two-time American Cancer Society Clinical Research Professor Award recipient. Dr. Pienta received a B.A. in human biology from Johns Hopkins University and an M.D. from the Johns Hopkins University School of Medicine, and is board certified in oncology.

What is Kenneth Pienta's net worth?: The estimated net worth of Kenneth Pienta is at least $16,050.00 as of March 15th, 2021. Dr. Pienta owns 15,000 shares of Cue Biopharma stock worth more than $16,050 as of December 18th. This net worth approximation does not reflect any other assets that Dr. Pienta may own. Learn More about Kenneth Pienta's net worth.
How do I contact Kenneth Pienta?: The corporate mailing address for Dr. Pienta and other Cue Biopharma executives is 21 ERIE STREET, CAMBRIDGE MA, 02139. Cue Biopharma can also be reached via phone at (617) 949-2680 and via email at [email protected]. Learn More on Kenneth Pienta's contact information.
Has Kenneth Pienta been buying or selling shares of Cue Biopharma?: Kenneth Pienta has not been actively trading shares of Cue Biopharma during the last quarter. Most recently, Kenneth Pienta sold 13,000 shares of the business's stock in a transaction on Monday, March 15th. The shares were sold at an average price of $15.10, for a transaction totalling $196,300.00. Following the completion of the sale, the insider now directly owns 15,000 shares of the company's stock, valued at $226,500. Learn More on Kenneth Pienta's trading history.
Who are Cue Biopharma's active insiders?: Cue Biopharma's insider roster includes Kerri-Ann Millar (CFO), Daniel Passeri (CEO), Kenneth Pienta (Insider), and Anish Suri (Insider). Learn More on Cue Biopharma's active insiders.
Are insiders buying or selling shares of Cue Biopharma?: In the last year, Cue Biopharma insiders bought shares 1 times. They purchased a total of 30,000 shares worth more than $30,900.00. The most recent insider tranaction occured on December, 16th when CEO Daniel R Passeri bought 30,000 shares worth more than $30,900.00. Insiders at Cue Biopharma own 12.3% of the company. Learn More about insider trades at Cue Biopharma.
Information on this page was last updated on 12/16/2024.

Kenneth Pienta Insider Trading History at Cue Biopharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/15/2021	Sell	13,000	$15.10	$196,300.00	15,000
2/16/2021	Sell	16,000	$15.15	$242,400.00	18,000
1/20/2021	Buy	2,720	$15.07	$40,990.40	4,720

Kenneth Pienta Buying and Selling Activity at Cue Biopharma

Cue Biopharma Company Overview

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $1.07

$1.01

$1.22

50 Day Range

MA: $1.32

$0.94

$1.87

2 Week Range

Now: $1.07

$0.45

$3.20

Volume

451,012 shs

Average Volume

453,450 shs

Market Capitalization

$67.78 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.66

Most People Are Dead Wrong.

From Brownstone Research | Ad